UPMC Enterprises has contributed to a $117m series B round for gene therapy developer Ring Therapeutics.
Ring Therapeutics, a US-based gene therapy developer, has secured $117m in a series B round backed by UPMC Enterprises, the commercialisation arm of University of Pittsburgh Medical Center, a health system closely aligned with the institution.
The round was also backed by Flagship Pioneering, Invus, Altitude Life Science Ventures, Partners Investment, funds and accounts advised by T Rowe Price Associates and unnamed others.
Founded in 2017 by Flagship Pioneering, Ring Therapeutics is working on anellovirus-based vector candidates for gene therapies.
Anellovirus causes no harm to the human body and vectors do not integrate with a patient’s existing DNA, thereby potentially overcoming some of the limitations currently presented by gene therapy. Ring is the first company to use anellovirus as the basis for drug candidates.
The company has not yet disclosed its initial target area but hopes to eventually cover a wide range of conditions such as…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
